Loading stock data…
Kailera Therapeutics, Inc. (KLRA)
$17.69+0.29 (+1.67%)
Market ClosedLast close Jul 24
Kailera Therapeutics, Inc.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $0 | $0 |
| Gross Profit | — | — |
| Operating Income | -$84.66M↓ | -$20.46M |
| Net Income | -$78.86M↓ | -$17.98M |
Peer Comparison
JNJUNHPFE
Fundamentals
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectabl...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.54B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
22.41%
Volume
Today's trading volume
663,347
Recent News
2 Beaten-Down GLP-1 Stocks to Buy on the Dip
Don't wait until clinical milestones send their share prices soaring.
Kailera Therapeutics (KLRA) is One of the Best IPO Stocks with Huge Upside Potential
Kailera Therapeutics Inc. (NASDAQ:KLRA) is one of the best IPO stocks with huge upside potential. On July 7, Kailera Therapeutics announced positive topline results from two Phase 3 clinical trials conducted by Hengrui Pharma for HRS-7535/KAI-7535, an oral small-molecule GLP-1 receptor agonist. In the obesity trial, participants achieved a mean weight loss of up to […]
Kailera weight loss pill trial results: Nausea sinks stock
Kailera stock dropped 10% after Phase 3 data showed roughly 70% of patients on HRS-7535 experienced nausea
Eli Lilly's Market Cap Balloons Again On This IPO's Setback
Eli Lilly shares hit a record high Tuesday after IPO stock Kailera Therapeutics posted lackluster test results for its weight-loss pill.
Update: Kailera Says Oral Small Molecule KAI-7535 Achieves Up to 11% Weight Loss in Phase 3 Trial; Shares Fall
(Updates with the latest stock movement in the first paragraph and headline.) Kailera Therapeutic